Will Waxman Offer Seven Years Of Exclusivity For Follow-On Biologics?
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised bill is expected shortly as Reps. Eshoo and Barton draw battle line against the Commerce Committee chairman.
You may also be interested in...
European Pharma Innovation May Be Outpacing U.S., Health Affairs Article Concludes
New Jersey professor analyzes proportion of R&D spending and proportion of NCEs in U.S., European nations and Japan, calling into question earlier Grabowski/Wang study reporting the U.S. had pulled ahead.
European Pharma Innovation May Be Outpacing U.S., Health Affairs Article Concludes
New Jersey professor analyzes proportion of R&D spending and proportion of NCEs in U.S., European nations and Japan, calling into question earlier Grabowski/Wang study reporting the U.S. had pulled ahead.
Follow The Follow-On Money: Obama’s Budget Has Modest Biogeneric Savings
The fiscal 2010 federal budget outlined by the Obama administration Feb. 25 takes a conservative view of the fiscal benefit of generic biologics - estimating they will contribute $9.2 billion over 10 years to help pay for health care reform